Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

Information

  • Research Project
  • 7685581
  • ApplicationId
    7685581
  • Core Project Number
    R43AI083117
  • Full Project Number
    1R43AI083117-01
  • Serial Number
    83117
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    4/1/2009 - 15 years ago
  • Project End Date
    9/30/2010 - 14 years ago
  • Program Officer Name
    FITZGIBBON, JOSEPH E.
  • Budget Start Date
    4/1/2009 - 15 years ago
  • Budget End Date
    9/30/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/18/2009 - 15 years ago

Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a multiplex label free platform for high-throughput HIV specific serum antibody detection of patient samples. To help Wasatch Microfludics reach this ultimate goal, this proposal will address the feasibility of performing high throughput label free detection of serum antibodies to a variety of HIV proteins through the application of a novel microfluidic spotting technology to available Surface Plasmon Resonance (SPR) array platforms. Specifically, a microfluidic flow cell array will be adapted for work with "real world" samples such as plasma, serum, and cell lysates. The flow cell array will have 48 channels and address an array of spots designed to support ongoing pre- clinical trials in non-human primates as well as HIV vaccine trials in humans. The development of a low cost, high throughput, multiplex assay to assess the development of humoral immune responses following vaccine administration is essential for comprehensive immunomonitoring. PUBLIC HEALTH RELEVANCE: The successful completion of this proposal will create a dramatic improvement in the ability to conduct multiplex SPR-based assays in drug discovery and proteomic research. On a greater scale, this will lead to improved diagnostic tools and reductions in the cost and time of drug development, by significantly improving the throughput of label free screening.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:100000\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WASATCH MICROFLUIDICS
  • Organization Department
  • Organization DUNS
    171205177
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84123
  • Organization District
    UNITED STATES